Ann: Continued promising results in PTX-100 TCL trial, page-13

PTX is still very much under the radar of the market. The fact that this announcement could barely make it to the Top 5 of HC posts is testament to that. If this had been an IMU or RAC or many of the other biotech announcement, it would already hit Top spot.

The fact that the FDA like this, that is more than enough already. And now with this confirmation of great outcomes for patients on this trial, PTX is now highly de-risked. If the outcome of the additional patients remains in current trajectory, fast-track approval is almost a given.

Good luck all. Above just my opinion.